| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Nivolumab |
| Brand | Opdivo® |
| Indication | Is licensed for the treatment of advanced renal cell carcinoma after prior therapy in adults |
| Assessment Process | |
| Rapid review commissioned | 27/04/2016 |
| Rapid review completed | 16/05/2016 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 28/10/2016 |
| NCPE assessment completed | 28/03/2017 |
| NCPE assessment outcome | Reimbursement Not Recommended at the Submitted Price |
The HSE has approved reimbursement following confidential price negotiations October 2017.
